scholarly journals Metastatic patterns and survival outcomes in patients with stage IV colon cancer: A population‐based analysis

2019 ◽  
Vol 9 (1) ◽  
pp. 361-373 ◽  
Author(s):  
Jiwei Wang ◽  
Song Li ◽  
Yanna Liu ◽  
Chunquan Zhang ◽  
Honglang Li ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Stage Iv ◽  
Population Based ◽  
Survival Outcomes ◽  
Metastatic Patterns

Comparison of irinotecan and oxaliplatin as adjuvant chemotherapy for patients with resectable synchronous colon cancer plus liver-confined metastases: A retrospective nationwide database study.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 624-624
Author(s):  
Yi-Hsin Liang ◽  
Yu Yun Shao ◽  
Ho-Min Chen ◽  
Ann-Lii Cheng ◽  
Mei-Shu Lai ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Chemotherapy ◽  
De Novo ◽  
Stage Iv ◽  
Similar Efficacy ◽  
Population Based ◽  
Research Database ◽  
Curative Surgery ◽  
Advanced Colon Cancer ◽  
Synchronous Colon Cancer

624 Background: Although irinotecan and oxaliplatin are both standard treatment for advanced colon cancer, it was unclear whether either was effective for patients with resectable synchronous colon cancer plus liver-confined metastasis (SCCLM) after curative surgery. Methods: We established a population-based cohort of patients diagnosed with de novo SCCLM between 2004 and 2009 by searching the database of Taiwan Cancer Registry and National Health Insurance Research Database of Taiwan. Patients who received curative surgery as the first therapy followed by chemotherapy doublets were classified into two groups: irinotecan group, or oxaliplatin group. Patient who received radiotherapy or did not receive chemotherapy doublets were excluded. Results: We included 6533 patients with de novo stage IV colon cancer, and 309 of them received chemotherapy doublets after surgery; 77 patients received irinotecan, and 232 patients received oxaliplatin as adjuvant chemotherapy. Patients in the irinotecan group and patients in the oxaliplatin group exhibited similar overall survival (OS) (median: not reached vs. 40.8 months, p = 0.151) and time to the next line of treatment (median: 16.5 months vs. 14.3 months, p = 0.349) in both univariate and multivariate analyses. Patients with resectable SCCLM had significant shorter median OS than patients with stage III colon cancer who received curative surgery and subsequent adjuvant chemotherapy but longer than patients with de novo stage IV colon cancer who received surgery only to the primary site and standard systemic chemotherapy ( p< 0.001). Conclusions: Either irinotecan or oxaliplatin exhibited similar efficacy for patients who received curative surgery for resectable SCCLM. [Table: see text]

Outcomes for metastatic colorectal cancer (mCRC) based on microsatellite instability.

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 759-759 ◽  
Author(s):  
Timothy Jay Price ◽  
Christos Stelios Karapetis ◽  
Young Joanne ◽  
Amitesh Roy ◽  
Rob Padbury ◽  
...  
Keyword(s):  
Microsatellite Instability ◽  
Early Stage ◽  
Stage Iv ◽  
Patient Characteristics ◽  
Population Based ◽  
Survival Outcomes ◽  
Treatment Pathways ◽  
Stage Disease ◽  
Stage Iv Disease ◽  
Population Based Registry

759 Background: Microsatellite instability (MSI) has been associated with improved survival outcomes in early stage CRC. In stage IV disease, MSI represents only 3-5% of cases and currently the prognostic implications are less clear. There is however evolving evidence that treatment pathways should include anti-PD-1 antibodies given the encouraging results in heavily pre-treated MSI mCRC patients. We undertook an analysis of the South Australian mCRC population based registry to explore the relevance of MSI status in this population based registry. Methods: The registry was analysed to assess patient characteristics and survival outcomes comparing patients with MSI or microsatellite stable (MSS) disease. K-M survival analysis was used to assess OS. Results: 4359 patients are registered on the data base. 598 (14%) patients had been tested for MSI. 62 (10.1%) of these patients had demonstrable MSI. Patient characteristics and outcomes are summarized in the table. There are statistically higher rates of right sided primary, poorly differentiated pathology and BRAF mutation in the MSI group associated with a trend to reduced survival. Chemotherapy and biological therapy received in the MSI v MSS groups was as follows; 5FU 31% v 25%, 5FU/irinotecan 17% v 12%, 5FU/oxaliplatin 52% v 58%, bevacizumab 31% v 42%, anti-EGFR 0 v 4.6%. Conclusions: The patient characteristics of MSI mCRC are in keeping with those previously reported. MSI in this population based mCRC registry is not associated with a favorable outcome as seen in earlier stage disease compared to patients with MSS disease. The trend to poorer outcomes may support routine testing and potentially an alternate treatment pathway, which may include PD-1 inhibitors.[Table: see text]

scholarly journals Revised TN Categorization for Colon Cancer Based on National Survival Outcomes Data

2010 ◽  
Vol 28 (2) ◽  
pp. 264-271 ◽  
Author(s):  
Leonard L. Gunderson ◽  
John Milburn Jessup ◽  
Daniel J. Sargent ◽  
Frederick L. Greene ◽  
Andrew K. Stewart
Keyword(s):  
Rectal Cancer ◽  
Colon Cancer ◽  
Survival Data ◽  
Population Based ◽  
Stage Iii ◽  
Survival Outcomes ◽  
Depth Of Invasion ◽  
Cancer Data ◽  
Colon And Rectal Cancer ◽  
Better Than

Purpose The sixth edition of American Joint Committee on Cancer (AJCC) Cancer Staging Manual for colon cancer subdivided stage II into IIA (T3N0) and IIB (T4N0) and stage III into IIIA (T1-2N1M0), IIIB (T3-4N1M0), and IIIC (anyTN2M0). Subsequent analyses supported revised substaging of stage III because of improved survival for T1-2N2 versus T3-4N2 and T4N1 survival was more similar to T3-4N2 than to T3N1. The AJCC Hindgut Taskforce sought population-based validation that depth of invasion and nodal status interact to affect survival. Patients and Methods Surveillance, Epidemiology, and End Results (SEER) population-based data from January 1992 to December 2004 for 109,953 colon cancer patients were compared with National Cancer Data Base (NCDB) data on 134,206 patients. T4N0 cancers were stratified by tumors that perforate visceral peritoneum (T4a) versus tumors that invade or are adherent to adjacent organs or structures (T4b). N1 and N2 were stratified by number of involved positive lymph nodes (N+): N1a/N1b (1 v 2-3), N2a/N2b (4 to 6 v ≥ 7). Five-year observed and relative survival data were obtained for each TN category. Results SEER colon cancer analyses confirm that patients with T1-2N0 cancers have better survival than T3N0, T3N0 better than T4N0, T1-2N2 better than T3-4N2, and T4bN1 similar to T4N2. Patients with T4a lesions have better survival than T4b by N category. The number of positive nodes affects survival for each T category. Conclusion This SEER population-based colon cancer analysis is highly consistent with rectal cancer pooled analysis and SEER rectal cancer analyses, supporting the shift of T1-2N2 lesions from IIIC to IIIA/IIIB, shifting T4bN1 from IIIB to IIIC, subdividing T4/N1/N2, and revising substaging of stages II/III. Survival outcomes by TN category for colon and rectal cancer are strikingly similar.

scholarly journals Different Anatomical Subsites of Colon Cancer and Mortality: A Population-Based Study

2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
Xing-kang He ◽  
Wenrui Wu ◽  
Yu-e Ding ◽  
Yue Li ◽  
Lei-min Sun ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Proportional Hazards ◽  
Proportional Hazards Model ◽  
Underlying Mechanism ◽  
Population Based ◽  
Cox Proportional Hazards ◽  
Cox Proportional Hazards Model ◽  
Survival Outcomes ◽  
Cancer Specific Survival ◽  
Kaplan Meier

Background. In terms of incidence and pathogenesis, right-sided colon cancer (RCC) and left-sided colon cancer (LCC) exhibit several differences. However, whether existing differences could reflect the different survival outcomes remains unclear. Therefore, we aimed to ascertain the role of location in the prognosis. Methods. We identified colon cancer cases from the Surveillance, Epidemiology, and End Results database between 1973 and 2012. Differences among subsites of colon cancer regarding clinical features and metastatic patterns were compared. The Kaplan-Meier curves were conducted to compare overall and disease-specific survival in relation to cancer location. The effect of tumour location on overall and cancer-specific survival was analysed by Cox proportional hazards model. Results. A total of 377,849 patients from SEER database were included in the current study, with 180,889 (47.9%) RCC and 196,960 (52.1%) LCC. LCC was more likely to metastasize to the liver and lung. Kaplan-Meier curves demonstrated that LCC patients had better overall and cancer-specific survival outcomes. Among Cox multivariate analyses, LCC was associated with a slightly reduced risk of overall survival (HR, 0.92; 95% CI, 0.92-0.93) and cancer-specific survival (HR, 0.92; 95% CI, 0.91-0.93), even after adjusted for other variables. However, the relationship between location and prognosis was varied by subgroups defined by age, year at diagnosis, stage, and therapies. Conclusions. We demonstrated that LCC was associated with better prognosis, especially for patients with distant metastasis. Future trails should seek to identify the underlying mechanism.

scholarly journals Primary Diffuse Large B-Cell Lymphoma of the Urinary Tract: A Population-Based Analysis

2021 ◽  
Vol 11 ◽  
Author(s):  
Zheng-Huan Liu ◽  
Lu-Chen Yang ◽  
Pan Song ◽  
Kun Fang ◽  
Jing Zhou ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Surgical Resection ◽  
Cell Lymphoma ◽  
Stage Iv ◽  
B Cell Lymphoma ◽  
Population Based ◽  
Survival Outcomes ◽  
Seer Database ◽  
Large B Cell Lymphoma ◽  
Large B Cell

ObjectiveDiffuse large B-cell lymphoma (DLBCL) is the most common histopathological type of non-Hodgkin’s lymphoma, which may arise from various extranodal sites. Little is known about the clinical characteristics and survival outcomes of primary DLBCL of the urinary tract (UT). Thus, we conducted this study to explore the independent prognostic factors of patients with UT-DLBCL using the Surveillance, Epidemiology, and End Results (SEER) database.Materials and MethodsWe searched the Surveillance, Epidemiology, and End Results (SEER) database for the data of patients diagnosed with UT-DLBCL between 1975 and 2016. Data, including demographic tumour stage and therapeutic strategies, such as surgical resection, radiation therapy, and chemotherapy, were collected. The impact of these factors on survival outcomes, including overall survival (OS) and disease-specific survival (DSS), was analysed using Kaplan–Meier curves.ResultsFour-hundred and eighty-nine patients who met the inclusion criteria were enrolled in the data analysis. The median age was 69 years old. Most cases of UT-DLBCL (72.39%) originated from the kidney, followed by the urinary bladder (24.95%). Both surgical resection and chemotherapy can significantly improve OS and DSS. Patients older than 75 years had the worst survival outcomes. Stage IV DLBCL may be a poor prognostic factor.ConclusionTo the best of our knowledge, this is the largest population-based study of UT-DLBCL. Advanced age, male gender, lack of surgical resection or chemotherapy, and stage IV DLBCL were poor prognostic factors.

Hematogenous Metastatic Patterns of Curatively Resected Colon Cancer Were Different from Those of Stage IV and Autopsy Cases

2013 ◽  
Vol 43 (4) ◽  
pp. 444-447 ◽  
Author(s):  
Sotaro Sadahiro ◽  
Toshiyuki Suzuki ◽  
Akira Tanaka ◽  
Kazutake Okada ◽  
Hiroko Kamata
Keyword(s):  
Colon Cancer ◽  
Stage Iv ◽  
Metastatic Patterns
Sign in / Sign up

Export Citation Format

Share Document